David Sinclair shares another side of himself. Compassion for all people. He wants to make sure that longevity technologies are available for all people, not just for the super wealthy and their pets. He also speaks of emerging elderly populations who can live well up until death rather than suffering for so long, and instead start new careers and hobbies.
Researchers have restored vision in animal by resetting some of the thousands of chemical marks that accumulate on DNA as cells age. The work, by Dr David Sinclair Lab, published in Nature Dec 2020, suggests a new approach to reversing age-related decline, by reprogramming some cells to a ‘younger’ state in which they are better able to repair or replace damaged tissue.
David A. Sinclair, Ph.D. A.O. is a tenured Professor in the Genetics Department at the Blavatnik Institute, Harvard Medical School, Boston & Co-Director of the Paul F. Glenn Center for Biology of Aging Research, honorary Professor at the University of Sydney, and co-founder of the journal Aging. He obtained a BS and a Ph.D. at UNSW, worked as a postdoctoral researcher at M.I.T., was hired at Harvard Medical School in 1999 as an Assistant Professor, and promoted to tenured Professor in 2008. His book Lifespan: Why We Age and Why We Don’t Have To, a NYT bestseller, is published in more than 20 languages.
Dr. Sinclair is an inventor on more than 50 patents, 170 papers, an h-index of 103 & cited 73,000+ times. His more than 40 awards include an Excellence in Teaching Award, Harvard, AFAR Fellowship, the Ellison Medical Foundation Scholarships, Genzyme Outstanding Achievement Award, Telluride Technology Award, Innovator of the Year, MERIT Award, Nathan Shock Award, Denham Harman Award, ASMR Medal, Advance Global Australian, Pioneer Award, TIME100’s most influential people, TIME magazine’s Heathcare 50, Irving Wright Award, AFAR, and is an Officer of the Order of Australia (AO).
He cofounded Sirtris Pharma (Cambridge; NASDAQ: SIRT, bought by GSK), Genocea (Cambridge, MA; NASDAQ: GNCA); Ovascience (NASDAQ: OVAS), Cohbar (Menlo Park NASDAQ: CWBR)), MetroBiotech, ArcBio, Liberty Biosecurity, Galilei, Immetas, EdenRoc Sciences and affiliates, and Life Biosciences and affiliates.
David Sinclair is a founder, equity owner, advisor to, director of, and/or inventor of patents licensed to Metrobiotech, Jumpstart Fertility, Liberty Biosecurity, Animal Biosciences, EdenRoc Sciences, Life Biosciences, Cohbar, Galilei, Spotlight Biosciences, Arc-Bio, Dovetail Genomics, Claret Bio, Selphagy, Iduna, Senolytic Therapeutics, Continuum, Immetas and a licensed unpaid HMS patent to Elysium Health.
#DavidSinclair #NMN #NAD #DrDavidSinclair #DrSinclair #ReverseAging#DrDavidSinclair #healthyaging #longevity #lifespan #healthspan #GMP #ReverseAging #ReverseAgingRevolution #NMNSupplier #NAD #NADH #LiveLonger #LiveHealthier #resveratrol #nmn
Comments are closed.